Background
==========

Inflammatory breast cancer (IBC) represents less than 10% of all breast cancers but is the most lethal form of the disease \[[@B1]\]. Evolution of this distinct and aggressive form of locally-advanced breast cancer depends on the type of neo-adjuvant chemotherapy but is overall poor \[[@B2]\]. IBC, classified T4d (stage IIIB) according to the TNM classification of the American Joint Committee of Cancer \[[@B5]\], is generally a rapidly growing tumor associated with cutaneous erythema and edema \[[@B2]-[@B4]\]. The inflammatory aspect is associated with highly angiogenic and angio-invasive properties and with the presence of dermal lymphatic emboli \[[@B5]\]. The high metastatic potential of IBCs suggests a high propensity of the tumor cells to migrate.

IBCs in Tunisia are characterized by a higher frequency and a higher aggressiveness than in European countries \[[@B6]-[@B8]\]. However, we did not observe any difference between Tunisian and French IBCs in the expression of five representative proteins (E-cadherin, Estrogen receptor (ER), MIB1, MUC1 and ERBB2) \[[@B9],[@B10]\].

In non-IBCs the five molecular subtypes (luminal A and B, basal, ERBB2-overexpressing and normal-like) are associated with different features, including response to chemotherapy and clinical outcome \[[@B11]\]. Basal and ERBB2 subtypes have the worst prognosis, followed by luminal B subtype. The proportion of these subtypes has been determined by gene expression profiling in European IBC. Around half the cases are of basal and ERBB2 subtypes.

The subtypes defined by gene expression analysis have also been defined at the protein level using various markers. A panel of antibodies (directed against ER, ERBB2, EGFR, basal cytokeratin CK5/6 and/or KIT) identifies basal tumors with high specifity \[[@B12]\]. Other markers such as P-cadherin, CK14, P53, CAV1, PR, MIB1 and moesin also identify basal tumors \[[@B13]-[@B16]\]. Reciprocally, the expression of ER and ERBB2 exclude basal tumors.

The high frequency of the two subtypes associated with poor prognosis, basal and ERBB2, explains only in part the fatal evolution of IBC. In IBCs, the luminal cases also have a poor prognosis. Only a factor common to all subtypes could explain IBC poor evolution.

In breast cancer, P-cadherin is associated with enhanced cell invasion, tumor aggressiveness, motility \[[@B17]\] and with a poor prognosis \[[@B18],[@B19]\]. P-cadherin mRNA is essentially expressed in basal carcinomas \[[@B20],[@B21]\].

The aims of this study were to determine the importance of breast carcinoma subtypes in IBC and to identify a factor that could explain the poor prognosis of IBC. We show that this factor could be associated with P-cadherin expression.

Methods
=======

Definition and selection of cases
---------------------------------

We collected a series of 91 Tunisian T4d tumors (TNM, UICC) treated between 1994 and 1998 at the Salah Azaiz Institute (ISA, Tunis, Tunisia). Paraffin-embedded specimens were collected prior chemotherapy. The presence of dermal lymphatic emboli was not mandatory. All patients received neo-adjuvant chemotherapy with anthracyclin-based (FEC 100 or FAC 50) regimen. Forty-three patients were metastatic at diagnosis and did not have complementary mastectomy. External beam radiation was done for all patients.

This series was compared with a consecutive series of 547 non-IBC cases deposited in tissue microarrays and previously used in a study of IBC cases that established IBC immunohistochemical profile \[[@B22]\] and for other purposes \[[@B23]\]. The 547 non-IBC cases were selected from cases included in the database of the Paoli-Calmettes Institute (IPC, Marseille, France) treated between 1990 and 1999. They were defined as T1, T2, T3 tumors (TNM, UICC), collected prior to adjuvant chemotherapy and embedded in paraffin.

Clinicopathological study
-------------------------

The clinical records were reviewed to determine the following patient characteristics: age, metastatic status, therapeutic regimen and survival. Pathological slides were reviewed by two pathologists (JJ, KM) according to the European guidelines \[[@B24]\]. Criteria evaluated were histological type, Elston-and-Ellis grade and, whenever possible, peritumoral vascular invasion.

Tissue Microarray construction
------------------------------

Two tissue microarrays (TMA) were used, one for the IBCs (ISA set) and the other one for the non-IBCs (IPC set). TMAs were prepared as described, with slight modifications \[[@B22]-[@B25]\]. Briefly, for each tumor, three representative tumor areas were carefully selected from a hematoxylin-eosin-safran stained section of a donor block. Core cylinders with a diameter of 0.6 mm each were punched from each of these areas and deposited into a recipient paraffin block using a specific arraying device (Alphelys, Plaisir, France). In addition to tumor tissues, the recipient blocks also received normal breast tissues and cell lines. Five-μm sections of the resulting microarray blocks were made and used for IHC analysis after transfer to glass slides.

Markers and immunohistochemistry
--------------------------------

Immunohistochemistry (IHC) was performed on 5-μm sections. The characteristics of the antibodies used and pre-treatment conditions are listed in Table [1](#T1){ref-type="table"}. A good concordance of IHC results has been reported between standard full tissue sections and TMA \[[@B21]\]. TMA data were evaluated by the mean score of two cores biopsies minimum for each case. The slides were dewaxed, pre-treated according to the supplier\'s recommendations (Table [1](#T1){ref-type="table"}). This was followed by the use of a streptavidin/biotin kit (Dako, Trappes, France). Diaminobenzidine, (DAB) or 3-amino-9-ethylcarbazole (AEC) was used as chromogen. Sections were counterstained with hematoxylin and coverslipped. Slides were evaluated under a light microscope by two independent observers on the Spot Browser device (Alphelys). Immunoreactivities were classified by estimating the percentage (P) of tumor cells showing characteristic staining (from 0%, undetectable level, to 100%, homogeneous staining) and by estimating the intensity (I) of staining 1, weak staining; 2, moderate staining; 3, strong staining). Results were scored by multiplying the percentage of positive cells by the intensity, i.e. by the so-called quick-score (Q). Internal positive controls such as epidermis or benign breast lobules were used. Hormone receptors (ER, PR) were positive when at least 1% of tumor cell nuclei were stained. For ERBB2, the Dako scale was used; staining was considered as positive when limited to a membrane staining of more than 10% of tumor cells and scored as 1+, 2+ or 3+ according to intensity and partial/complete staining. Protein overexpression was considered for 2+ and 3+. Cytokeratin 5/6, cytokeratin 14 and EGFR were scored positive if any (weak or strong) membranous invasive carcinoma cell staining was observed. Caveolin 1 (CAV1) and Caveolin 2 (CAV2) status of tumor cells was evaluated by light microscopy as either positive (any tumor cell with IHC staining) or negative. For CAV1 negative cases, endothelial cells and interstitial fibroblasts were used as internal positive controls.

###### 

Main characteristics of the antibodies used in immunohistochemistry.

  Protein (Clone)              Antibody   Origin                        Clone      Pre-treatment                              Dilution   Location of staining   Normal
  ---------------------------- ---------- ----------------------------- ---------- ------------------------------------------ ---------- ---------------------- ---------------------
  Caveolin 1                   mmb        Santa Cruz                    N20        Micro waves (10 min), tps citrate pH = 6   1/1000     cytoplasm              m.e.c+
  Caveolin 2                   mmb        Transduction Laboratories     65         Target retrival solution (98°C, 40 min)    1/50       cytoplasm              m.e.c+
  Cytokeratin 5/6              mmb        Dako                          D5/16 B4   Target retrival solution (98°C, 40 min)    1/10       cytoplasm              m.e.c +
  Cytokeratin 14               mmb        Newcastle UK                  LL002      Target retrival solution (98°C, 40 min)    1/300      Cell membrane          m.e.c+
  EGFR                         mmb        Zymed                         3IG7       Target retrival solution (98°C, 40 min)    1/10       membrane               m.e.c +
  ERBB2                        mmb        Dako Herceptest Ltd           AO485      Target retrival solution (98°C, 40 min)    1/500      membrane               \-
  Estrogen receptor (ER)       mmb        Novocastra laboratories Ltd   6F11.2     Target retrival solution (98°C, 40 min)    1/60       nucleus                m.e.c- and luminal+
  P53                          mmb        Dako                          DO-1       Target retrival solution (98°C, 40 min)    1/4        nucleus                \-
  P-cadherin                   mmb        Transduction laboratories     56         Target retrival solution (98°C, 40 min)    1/75       Cell membrane          m.e.c +
  Progesterone receptor (PR)   mmb        Dako                          PFR 636    Target retrival solution (98°C, 40 min)    1/80       Nucleus                m.e.c- and luminal+
  Ki67                         mmb        Dako                          KI-67      Target retrival solution (98°C, 40 min)    1/100      Nuclear                \-
  MUC1                         mmb        Transgen                      H23        none                                       1/1000     Apical/Cytoplamic      \+

mmb: mouse monoclonal antibody

m.e.c: myoepithelials cells

Statistical analysis
--------------------

Data were summarized by frequencies and percentages for categorical variables. Furthermore, for continuous variables the means, the median and range were computed. To investigate the association between categorical variables, univariate statistical analysis were done, using Pearson\'s Chi-2 test or Fisher\'s exact test for small sample size and using non-parametric Mann and Whitney test for continuous variables \[[@B26]\]. Multivariate analysis was done using logistic regression model with backward stepwise selection procedure to evaluate the effect of interactions between the different variables. All statistical tests were two-sided at the 5% level of significance. All the statistical analyses were done using R.2.4.0 statistical software\[[@B27]\].

Results
=======

Characteristics of patients and tumors
--------------------------------------

A total of 91 IBC and 547 non-IBC informative cases from women patients were analyzed. Their characteristics are listed in Table [2](#T2){ref-type="table"}. Age was different (p \< 0.001) for the two series: for IBCs, age ranged from 22 to 76 years (mean 43.47 years) whereas for non-IBCs, age ranged from 25 to 94 years (mean 59.43 years).

###### 

Clinical and histological characteristics of IBC and non-IBC cases.

  Variables                   IBC          Non-IBC          p
  --------------------------- ------------ ---------------- ---------
  Age                                                       
  Min                         22           25               
  Max                         76           94               \<0.001
  Mean                        43.47        59.43            
  Standard deviation          9.43         12.77            
  Grade                                                     
  I                           3(3.3%)      176(32.41%)      
  II                          60(65.93%)   229(42.17%)      \<0.001
  III                         28(30.77%)   138(25.41%) \*   
  Histological type                                         
  Invasive ductal carcinoma   86(94.5)     386(70.56)       
  Micropapillary carcinoma    5(5.5)       0                
  Lobular carcinoma           0            72(13.16)        
  Tubular carcinoma           0            37(6.76)         \<0.001
  Mixt                        0            24(4.38)         
  Medullary carcinoma         0            8(1.46)          
  Others                      0            20(3.65)         

\* 4 cases non valuable for the histoprognostic grade.

Among the 91 IBCs, 86 were invasive ductal carcinomas (IDC) and 5 were invasive micropapillary carcinomas. The distribution of histological types in non-IBCs was representative of unbiased populations. IBCs were more frequently of grade II and III (65.93%, 30.77%) than non-IBCs (p \< 0.001) (Table [2](#T2){ref-type="table"}).

Protein expression profiles of IBC and non-IBC and immunohistochemical subtypes
-------------------------------------------------------------------------------

IHC was done on IBCs and non-IBCs using three TMA slides for each marker. We compared the expression of the markers only for the infiltrating ductal cases, i.e. 86 IBC cases and 386 non-IBC cases. We observed differences between the two series for: ER negativity (53.85% IBCs, 26.26 % non-IBCs; p \< 0.001), PR negativity (52.86% IBCs, 35.39% non-IBCs; p \< 0.01), ERBB2 positivity (33.33% IBCs, 14.49% non-IBCs; p \< 0.001), CK14 positivity (19.15% IBCs, 5.45% non-IBCs; p \< 0.01), P-cadherin positivity (75.93% IBCs, 48.16% non-IBCs; p \< 0.001) (Figure [1](#F1){ref-type="fig"}) and proliferative rate expressed by a Ki67 index (MIB1) higher than 20% (41.1% IBCs, 12.98% non-IBCs; p \< 0.001) (Table [3](#T3){ref-type="table"}).

###### 

Immunohistochemical comparison of the different markers used in the two series

                          IBC           Non-IBC        p value
  ------------ ---------- ------------- -------------- ---------
                          n (%)         n (%)          
  ER           Negative   42 (53.85%)   99 (26.26%)    \<0.001
               Positive   36 (46.15%)   278 (73.74%)   
  PR           Negative   37 (52.86%)   132 (35.39%)   \<0.01
               Positive   33 (47.14%)   241 (64.61%)   
  ERBB2        0--1       48 (66.67%)   301 (85.51%)   \<0.001
               2--3       24 (33.33%)   51 (14.49%)    
  EGFR         Negative   57 (77.03%)   240 (75.24%)   \>0.05
               Positive   17 (22.97%)   79 (24.76%)    
  CK5/6        Negative   47 (61.04%)   191 (67.25%)   \>0.05
               Positive   30 (38.96%)   93 (32.75%)    
  CK14         Negative   38 (80.85%)   295 (94.55%)   \<0.01
               Positive   9 (19.15%)    17 (5.45%)     
  P-cadherin   Negative   13 (24.07%)   169 (51.84%)   \<0.001
               Positive   41 (75.93%)   157 (48.16%)   
  P53          Negative   43 (58.11%)   253 (69.7%)    \>0.05
               Positive   31 (41.89%)   110 (30.3%)    
  MUC1         Negative   5 (6.67%)     42 (12.84%)    \>0.05
               Positive   70 (93.33%)   285 (87.16%)   
  CAV1         Negative   22 (31.43%)   105 (31.16%)   \>0.05
               Positive   48 (68.57%)   232 (68.84%)   
  CAV2         Negative   45 (90%)      212 (89.83%)   \>0.05
               Positive   5 (10%)       35 (10.17%)    
  MIB1         ≤20        43 (58.9%)    295 (87.02%)   \<0.001
               \>20       30 (41.1%)    44 (12.98%)    

![**Immunohistochemistry on tissue microarray sections of breast cancers of the luminal subtype**. A: Expression of estrogen receptor in 100% of tumor cells in a grade III inflammatory case. B: Strong expression of P-cadherin in 100% of tumor cells in the same case. C: Higher magnification showing the cell membrane localization. D: Expression of estrogen receptor in 100 % of tumor cells in a more differentiated (grade II) inflammatory case. E: Moderate expression of P- cadherin in 100% of tumor cells in the same case. F: Higher magnification showing the cell membrane localization. G: Luminal grade II non inflammatory case with 100% estrogen receptor-positive cells. H: Absence of expression of P-cadherin in the same non inflammatory case; note the positive internal control on myoepithelial cells of the normal duct. I: Higher magnification showing the cell membrane localization of the myoepithelial cells by contrast to the negativity of the luminal normal cells.](1471-2407-8-28-1){#F1}

We classified tumors in terms of subtypes based on ER/PR and ERBB2 IHC expression \[[@B12],[@B28]\]. The analysis was restricted to the infiltrating ductal cases (86 IBC and 386 non-IBC), and allowed a classification in three groups (Table [4](#T4){ref-type="table"}). ER-positive and PR-positive tumors were classified as luminal. ERBB2-positive tumors were classified as ERBB2-overexpressing. ER-negative and ERBB2-negative (double negative) were considered as basal (ER-/ERBB2-). Using this protein-based definition of subtypes, 33.8% of IBCs vs 15.93 % of non-IBCs (p \< 0.001) were basal, 33.33 % of IBCs vs 14.49% of non-IBCs (p \< 0.001) were ERBB2-overexpressing, and 29.33% of IBCs vs 58.93% of non-IBCs (p \< 0.001) were luminal.

###### 

Immunohistochemical classification in molecular subtypes of the two series

                               IBC           Non-IBC        
  ---------------------------- ------------- -------------- ---------
  Basal cases (ER-, ERBB2-)    24 (33.8%)    58 (15.93%)    \<0.001
  ERBB2-overexpressing cases   24 (33.33%)   51 (14.49%)    \<0.001
  Luminal cases (ER+, PR+)     22 (29.33%)   221 (58.93%)   \<0.001

Expression of P-cadherin in IBC and non-IBC
-------------------------------------------

### Univariate analyses

Among various markers tested, the expression of P-cadherin was worth further investigation. The expression of P-cadherin varied according to the subtype and the IBC status in infiltrating ductal cases. The expression of P-cadherin in the basal subtype was 95% for IBCs vs 69% for non-IBCs (p = 0.02). There was no difference between IBCs and non-IBCs in the ERBB2-overexpressing subtype. In luminal tumors, P-cadherin was expressed in 82 % of IBCs vs 43% of non-IBCs (p \< 0.01) (Table [5](#T5){ref-type="table"}). Finally, we found a strong correlation between P-cadherin and Ki67/MIB1 (p = 0.0004).

###### 

Comparison of P-cadherin expression in different breast cancer subtypes

                               IBC          Non-IBC       p-value
  ---------------------------- ------------ ------------- ---------
  Basal cases (ER-,ERBB2-)     18/19(95%)   35/51(69%)    0.05
  ERBB2-overexpressing cases   9/13(69%)    32/47(68%)    NS
  Luminal cases (ER+, PR+)     14/17(82%)   84/197(43%)   \<0.01

### Multivariate analyses

We used a logistic regression stepwise selection with clinical and biological factors (Table [6](#T6){ref-type="table"}). The most discriminant factors for IBC status were grade (Odd ratio, OR = 6.28, p = 0.081), and P-cadherin (OR = 4.21, p = 0.013), MIB1 (OR = 2.82, p = 0.018), and ER (OR = 1.00, p = 0.053) expression. In a logistic regression by backward stepwise selection using biological factors only, the factors discriminating IBC from non-IBC were P-cadherin (OR = 4.9, p = 0.0019), MIB1 (OR = 3.6, p = 0.001), CK14 (OR = 2.7, p = 0.02), and ERBB2 (OR = 2.3, p = 0.06).

###### 

Logistic regression using prognostic and biological factors to best determine IBC status.

  With histoprognostic factors   Regression coefficient   OR     p       Without histoprognostic factors   Regression coefficient   OR     p
  ------------------------------ ------------------------ ------ ------- --------------------------------- ------------------------ ------ -------
  Grade (II-III)                 1.84                     6.28   0.081   P-cadherin \>0                    1.59                     4.90   0.001
  P-cadherin \>0                 1.44                     4.21   0.013   MIB 1 \>20                        1.28                     3.60   0.001
  MIB1 \>20                      1.04                     2.82   0.018   CK14 \>0                          1.02                     2.79   0.028
  ER \<0                         -0.87                    1.00   0.053   ERBB2 (2--3)                      0.84                     2.34   0.063

Discussion
==========

The identification of a specific IBC profile could improve the diagnosis, treatment and evolution of this aggressive form of locally-advanced breast cancer with high metastatic potential. In Tunisia, IBCs are frequent and have a worse prognosis than in European countries. However, in a previous study, we did not observe any difference in protein expression between IBCs from France and Tunisia \[[@B10]\]. Five major molecular subtypes have been defined by gene expression profiling \[[@B11],[@B20],[@B29]\]. Basal and ERBB2 subtypes represent each about 20% of cases. These subtypes could also be recognized at the protein level, with a very good correlation with RNA analyses. IHC-defined subtypes also show differences in prognosis in non-IBCs: basal and ERBB2-overexpressing subtypes are associated with poor prognosis. To better understand the specificity and the poor prognostic of IBCs in general and Tunisian IBCs in particular, we studied by IHC on TMA the expression of proteins commonly used as markers for molecular subtypes.

We studied several markers but eventually used a simple operational definition based on ER and ERBB2 expression. The basal subtype was defined as negative for both ER and ERBB2. In non-IBCs basal and ERBB2 subtypes represent around 40% of cases. We compared only infiltrating ductal cases. We found differences in the proportion of subtypes in Tunisian IBCs. Basal and ERBB2 subtypes made up each about one-third of the cases. Overall, these data and those of the literature show an over-representation of basal and ERBB2 cases in IBCs as compared with non-IBCs \[[@B30],[@B31]\].

However, the high proportion of basal and ERBB2 subtypes is not sufficient *per se*to explain IBC prognosis. Only a factor common to all subtypes could explain IBC poor evolution. Surprisingly, we found that luminal IBCs express basal markers such as P-cadherin. Indeed, P-cadherin expression was not only higher in basal IBCs than in basal non-IBCs (95%/69%) but also higher in the IBC luminal cases (82%/42%). The logistic regression analysis showed that P-cadherin was the most representative marker of IBC.

P-cadherin is one of the most specific markers of myoepithelial cells and is associated with basal subtype. The frequency of P-cadherin IHC expression varies from 20% in initial works \[[@B32]\] to 40% in more recent series\[[@B33]\]. This percentage exceeds that of basal tumors suggesting that P-cadherin could also be expressed in non-basal cases. P-cadherin expression in breast cancer correlates with high grade, lack of ER/PR expression, increased tumor aggressiveness, high proliferation rate, and poor survival. P-cadherin is associated with MIB1, EGFR, ERBB2, P53 and CK5/6 expression \[[@B23]\]. This expression may be due to hypomethylation of the gene promoter \[[@B18]\]. Deregulated P-cadherin expression may alter epithelial cell behavior thereby contributing to a more aggressive tumor cell phenotype and poor survival \[[@B34]\]. P-cadherin has pro-invasive activity in the MCF-7/AZ luminal breast cancer cell line, through interaction with signaling proteins bound to its juxtamembrane domain. ICI182,780, which blocks ER, induces increased expression of P-cadherin, which is associated with *in vitro*invasion\[[@B35]\]. Overexpressed P-cadherin increases motility of pancreatic cancer cells by interacting with p120ctn and subsequent activation of RHO GTPases \[[@B36]\]. Activation of RHO GTPases has been observed in IBC. Overexpression of RHOC is associated with the loss of expression of WISP3 \[[@B37],[@B38]\], which acts as a tumor suppressor. RHOC is overexpressed in over 90% of IBCs vs 36% of non-IBCs. RHOC activity requires NFκB stimulation \[[@B39]\]. P-cadherin transgenic mice do not develop mammary tumors spontaneously. When mammary tumors are induced in the P-cadherin transgenic mice through breeding with the MMTV/neu transgenic mouse, the tumors do not express P-cadherin. This indicates that P-cadherin is not *per se*an oncogene \[[@B34]\].

Conclusion
==========

Expression of P-cadherin in luminal IBC may indicate that the tumor cells derive from a stem/basal cell that has acquired ER expression and a luminal phenotype but retained some basal features. This suggests that IBC derives from a basal cell and progress along a specific oncogenic pathway allowing partial differentiation. This origin may be associated with specific IBC features and aggressiveness even in luminal cases. Although it may contribute, P-cadherin expression may be a sign of but not the reason for this aggressiveness.
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